BACKGROUND: Osteosarcoma (OS) is the most common malignant pediatric bone tumor. The identification of novel biomarkers for early prognostication will facilitate risk-based stratification and therapy. This study investigated the significance of circulating cytokines/chemokines for predicting the prognosis at the initial diagnosis. METHODS: Luminex assays were used to measure cytokine/ chemokine concentrations in blood samples from a discovery cohort of OS patients from Texas Children's Hospital (n 5 37) and an independent validation cohort obtained from the Children's Oncology Group (n 5 233). After the validation of the biomarkers, a multivariate model was constructed to stratify the patients into risk groups. RESULTS: The circulating concentrations of C-X-C motif chemokine ligand 10 (CXCL10), Fms-related tyrosine kinase 3 ligand (FLT3LG), interferon g (IFNG), and C-C motif chemokine ligand 4 (CCL4) were significantly associated with overall survival in both cohorts. Among these candidates, CXCL10 and FLT3LG were independent of the existing prognostic factor, metastasis at diagnosis, and CCL4 further discriminated cancer cases from controls. CXCL10, FLT3LG, and the metastatic status at diagnosis were combined to develop a multivariate model that significantly stratified the patients into 4 distinct risk groups (P 5 1.6 3 10 28 ). The survival analysis showed that the 5-year overall survival rates for the low-, intermediate-, high-, and very high-risk groups were 77%, 54%, 47%, and 10%, respectively, whereas the 5-year event-free survival rates were 64%, 47%, 27%, and 0%, respectively. Neither CXCL10 nor FLT3LG tumor expression was significantly associated with survival. CONCLUSIONS: High circulating levels of CXCL10 and FLT3LG predicted worse survival for patients with OS. Because both CXCL10 and FL3LG axes are potentially targetable, further study may lead to novel risk-based stratification and therapy for OS. Cancer 2017;123:144-54. V C 2016 American Cancer Society.
INTRODUCTION
Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents. 1 Currently, 10-year overall survival rates are 60% to 70% for all patients 2 and only approximately 20% for patients with metastatic disease, 3 which is a known prognostic factor at the time of diagnosis. The other clinical prognostic factor is the response to neoadjuvant chemotherapy, and that is measured at the time of definitive surgery. The survival of metastatic patients has not significantly improved in recent decades, mainly because therapeutic options for metastasis are very limited. Therefore, all OS patients receive the same chemotherapy at diagnosis despite their clinical risks. In addition, altering postoperative chemotherapy on the basis of the response to neoadjuvant chemotherapy has not improved outcomes, and this highlights the importance of tailoring treatment at diagnosis rather than after chemotherapy resistance has developed. 4 We believe that a promising strategy is the discovery of biomarkers for high-risk OS patients, so that the biomarker-associated pathways can be potentially targeted.
Although many previous studies have focused on tumors, blood-based biomarkers have become increasingly important in cancer research. 5 Circulating biomarkers can be obtained through noninvasive procedures and contain molecular information not only from the tumor but also from the host's immune system and tumor microenvironment. In OS, levels of serum alkaline phosphatase 6 and lactate dehydrogenase 7 have been proposed as prognostic biomarkers. More recently, circulating microRNA levels (ie, miR-195-5p and miR-320a levels) have been proposed for early detection and tumor burden monitoring. 8 However, no biomarkers are currently used to guide clinical decisions and therapies in clinics.
Our group previously identified CXC chemokines that were significantly elevated in OS patients' peripheral blood and tumors. 9 We further demonstrated that the "cell adhesion/chemokines and adhesion" pathway was commonly associated with metastatic OS. 10 Therefore, we reasoned that cytokines/chemokines might also serve as biomarkers for OS with a poor prognosis. Recent studies have demonstrated the roles of these proteins in tumorigenesis and cancer progression. 11 Specifically, OS research has revealed complex roles of chemokine ligand/ receptor axes related to metastasis and prognosis. 12 In this study, we show that C-X-C motif chemokine ligand 10 (CXCL10), Fms-related tyrosine kinase 3 ligand (FLT3LG), interferon c (IFNG), and C-C motif chemokine ligand 4 (CCL4) have prognostic significance for OS patients. A combined model using CXCL10, FLT3LG, and the metastatic status significantly improves prognostic significance in comparison with metastasis alone.
MATERIALS AND METHODS

Patients and Samples
Plasma samples for the discovery cohort were collected at the initial diagnosis from 37 OS patients at Texas Children's Hospital who consented to participate under an institutional review board-approved protocol. The patients were 5 to 18 years old with a median follow-up time of 25 months. Samples were collected in ethylenediaminetetraacetic acid-containing tubes at room temperature and were immediately centrifuged at 1000 rpm for 10 minutes. Plasma supernatant was stored at -808C until use. The Children's Oncology Group provided 233 validation OS serum samples collected at diagnosis under 3 collection/treatment protocols (P9851, P9754, and AOST0121) from multiple institutions. Patients were 2 to 31 years old with a median follow-up of 49 months. The use of these blood samples in this study was approved by institutional review board. Chi-square tests were used to compare discovery and validation set clinical parameters (Table 1) . Twelve serum samples from healthy 18-year-old donors (Equitech-Bio) and 5 plasma samples from noncancerous pediatric patients (ie, well-child checkup, flu, constipation, gastroenteritis, and febrile seizure) collected from Texas Children's Hospital were used as normal controls.
Cytokine and Chemokine Assays
This study used the Luminex suspension bead array platform (Luminex Corp, Austin, Texas), which enabled the simultaneous analysis of many proteins per sample with a sensitivity equal to or higher than that of a traditional enzyme-linked immunosorbent assay. 13 A human 39-plex cytokine panel (Millipore, Billerica, MA) was used to detect the following cytokines/chemokines: granulocytemacrophage colony-stimulating factor, granulocyte colony-stimulating factor, IFNG, interleukin 1a (IL-1a), IL-1Ra, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-12p40, IL-13, IL-15, IL-17, monocyte chemoattractant protein 1 (MCP-1), MCP-3, macrophage-derived chemokine (MDC), tumor necrosis factor a (TNFa), TNFb, transforming growth factor a, eotaxin, IFNa2, interferon-inducible protein 10/ CXCL10, macrophage inflammatory protein 1a (MIP- Staining/scoring methods were performed as previously described. 9 The staining score cutoff that best separated patients into 2 equal groups defined low and high expression for each candidate marker. The data were then independently analyzed with respect to overall survival.
Data Analysis
Cytokine/chemokine concentrations were arcsinhtransformed with out-of-range low values set to 0 and out-of-range high values set to the maximum detected value. In the discovery cohort, an optimal cutoff for each protein was chosen with the Gini index criterion from the rpart package in R 14 for Kaplan-Meier analysis with respect to overall survival. Proteins that stratified patients into high-and low-risk groups with BenjaminiHochberg-corrected log-rank P values < .1 were selected for validation. In validation, the predetermined cutoff concentrations were used for Kaplan-Meier analysis with respect to overall survival and event-free survival (EFS) with the 1-tailed log-rank statistic. Events were defined as either death or relapse. The validated biomarkers were further analyzed with pairwise Pearson correlations.
A multivariate model was then constructed with the metastasis-only model as the baseline and with the stepwise Bayesian information criterion with backward selection to select candidates that improved prognostic prediction. Selected markers were confirmed to be independent of initial metastasis with the nested likelihood ratio test. A final model was constructed by the assignment of patient risk scores (0, 1, 2, or 3) based on the number of risk factors present (CXCL10 > cutoff, FLT3LG > cutoff, and/or metastasis at diagnosis). The 4 risk groups were defined as low-, intermediate-, high-, and very high-risk, which corresponded to risk scores of 0, 1, 2, and 3, respectively. Model significance was determined with the 1-tailed log-rank statistic, whereas the significance of individual hazard ratios (HRs) was determined with the Wald statistic. The association of each biomarker with metastasis at diagnosis, histologic response to chemotherapy, and cancer cases versus controls was evaluated with Welch's t test. Unless specified otherwise, P < .05 was considered significant.
RESULTS
We investigated circulating levels of 39 cytokines/chemokines in discovery and validation cohorts with no significantly different clinical characteristics (Table 1 ). In the validation cohort, patient survival significantly correlated with the collection/treatment protocol (P < .05), and this reflected the fact that one protocol (AOST0121) Abbreviations: BH, Benjamini-Hochberg; CCL4, C-C motif chemokine ligand 4; CXCL10, C-X-C motif chemokine ligand 10; FGF-2, fibroblast growth factor 2; FLT3LG, Fms-related tyrosine kinase 3 ligand; HR, hazard ratio; IFNG, interferon g; IL, interleukin; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; MIP-1a, macrophage inflammatory protein 1a; NA, not applicable; TGFa, transforming growth factor a; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. a The proteins are arranged in ascending order of their P values in validation. b There were no events in the low-CCL4 patient group from the discovery cohort.
Original Article contained only metastatic patients and that another (P9754) contained only nonmetastatic patients. However, the survival of metastatic and nonmetastatic patients from the third protocol (P9851) was similar to the survival of the patients from AOST0121 and P9754, respectively, and the protocols did not significantly correlate with overall survival after correction for the metastatic status (Supporting Fig. 1 [see online supporting information]). Furthermore, the time of sample collection was not significantly associated with survival.
CXCL10, FLT3LG, IFNG, and CCL4 Significantly Correlate With Survival
In the discovery cohort, 26 proteins were associated with overall survival after multiple-testing correction (Table 2) . Notably, the expression of all but one (MDC/CCL22) of the proteins had a HR > 1, and this linked high expression with a poorer outcome. With the same concentration cutoffs, these candidate biomarkers were examined in the validation cohort. The results showed that higher levels of CXCL10 (P 5 Figure 1 . Kaplan-Meier analysis of significant proteins with respect to overall and event-free survival in the osteosarcoma validation cohort. Higher values for all proteins corresponded to a worse prognosis (ie, HR > 1). All analyses reached statistical significance (P < .05) except for CCL4 in event-free survival. CCL4 indicates C-C motif chemokine ligand 4; CXCL10, C-X-C motif chemokine ligand 10; FLT3LG, Fms-related tyrosine kinase 3 ligand; HR, hazard ratio; IFNG, interferon g.
3 10
24
), FLT3LG (P 5 4.6 3 10 23 ), IFNG (P 5 .013), and CCL4 (P 5 .037) significantly correlated with poorer overall survival (Table 2) . CXCL10, IFNG, and FLT3LG also significantly correlated with EFS (Fig. 1) . Five-year overall survival and EFS rates for the high-and low-biomarker expression groups and for patients stratified by metastasis are listed in Table 3 . The concentration cutoffs defining the high-and low-expression groups were 328 pg/mL (70th percentile; range, 43-3044 pg/mL) for CXCL10, 16 pg/mL (63rd percentile; range, 0-17939 pg/ mL) for IFNG, 17 pg/mL (77th percentile; range, 0-1780 pg/mL) for FLT3LG, and 50 pg/mL (38th percentile; range, 8-2901 pg/mL) for CCL4. No biomarker significantly differed between OS and control samples other than CCL4 (Fisher's exact test: OR, 25.6; P 5 5 3 10 26 ; Supporting Fig. 2 [see online supporting information]). All biomarkers remained significantly correlated with overall survival when we controlled for the protocol and the time of collection.
In a pairwise correlation analysis, FLT3LG, IFNG, and CCL4 were highly correlated with one another (R 5 0.5-0.61), and this indicated that there may be prognostic redundancy, whereas CXCL10 showed a weak correlation with all others (R < 0.3; Supporting Fig. 3 [see online supporting information]). According to an examination of correlations with known prognostic factors, CXCL10 alone was significantly correlated with metastasis at diagnosis (P < .05), whereas none of the 4 biomarkers were correlated with the histological response to chemotherapy (Supporting Table 1 [see online supporting information]).
Multivariate Model Combining CXCL10, FLT3LG, and Metastatic Status Significantly Stratifies OS Patient Survival
In the validation cohort, the 5-year overall survival rates for nonmetastatic and metastatic patients at diagnosis were 67% and 44%, respectively, and the 5-year EFS rates were 57% and 30%, respectively; these findings were similar to the results of previous studies 15, 16 ( Fig. 2 and Table  3 ). We sought to develop a novel stratification model by selecting biomarkers that added prognostic value to metastasis. For both overall survival and EFS, FLT3LG and CXCL10 increased the prognostic value of the metastatic status alone on the basis of the Bayesian information criterion, which we validated with the nested likelihood ratio test. (chi-square test: P < .05; Supporting Table 2 [see online supporting information]). However, CCL4 and IFNG did not, and this verified the expectation from the correlation analysis. We thus combined CXCL10 and FLT3LG into a 2-biomarker model, which significantly stratified OS patients with high expression of neither CXCL10 nor FLT3LG, high expression of CXCL10 or FLT3LG, or high expression of both CXCL10 and FLT3LG (P < .05; Fig. 3A) . Furthermore, this model significantly stratified both metastatic and nonmetastatic patients separately by survival (P < .05; Fig. 3B,C) . Abbreviations: CCL4, C-C motif chemokine ligand 4; CXCL10, C-X-C motif chemokine ligand 10; FLT3LG, Fms-related tyrosine kinase 3 ligand; IFNG, interferon g. a High risk indicates a concentration higher than the cutoff or metastasis; low risk indicates a concentration lower than the cutoff or no metastasis. Numbers in parentheses indicate 95% confidence intervals.
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Consequently, we created a multivariate model by adding the metastatic status to the 2 biomarker model; this resulted in stratification into 4 risk groups: low risk, intermediate risk, high risk, and very high risk. The 5-year overall survival rates for these risk groups were 77%, 54%, 47%, and 10%, respectively, whereas the 5-year EFS rates were 64%, 47%, 27%, and 0%, respectively. This indicated a final model with greater prognostic significance than the metastatic status alone (P 5 1.6 3 10
28
; Figure 2 and Table 3 ).
CXCL10 and FLT3LG Are Expressed in the Majority of OS Tissue Samples
Using a tissue microarray, we found that 52% and 86% of OS tissues had at least moderate intensity scores for FLT3LG and CXCL10, respectively. Similarly, in 54% and 89% of the tissues, at least 50% of the tumor cells showed staining for FLT3LG and CXCL10, respectively (see Fig. 4 and Supporting Table 3 [see online supporting information]). Unlike the blood results, the tumor intensity and proportion of neither FLT3LG nor CXCL10 significantly correlated with overall survival (see Supporting  Fig. 4 [see online supporting information]).
DISCUSSION
Precision medicine through the combination of molecular biomarkers and targeted therapies has become increasingly important in modern cancer treatment. Ideally, biomarkers can also act as potential targets (eg, epidermal growth factor receptor mutations and mammalian target of rapamycin). [17] [18] [19] However, because of tumor heterogeneity and genome instability, the identification and validation of clinically relevant tumor biomarkers in OS Figure 2 . Kaplan-Meier analysis of (Left) the metastatic status at diagnosis and (Right) the multivariate risk model (including a CXCL10 level higher than the cutoff, an FLT3LG level higher than the cutoff, and metastatic status) for both (Top) overall survival and (Bottom) event-free survival. For metastasis, low-risk patients and high-risk patients corresponded to those with localized and metastatic disease at diagnosis, respectively. HR 1, HR 2, and HR 3 refer to the patients with 1, 2, and 3 risk factors, respectively, in comparison with the baseline hazard of 0 risk factors. CXCL10 indicates C-X-C motif chemokine ligand 10; FLT3LG, Fmsrelated tyrosine kinase 3 ligand; HR, hazard ratio.
have been very difficult. 1, 20, 21 Thus, no biomarkers beyond radiographically visible metastasis at diagnosis have yet been translated to the clinic to stratify patients and guide therapeutic options. 15 In this study, we demonstrated that high levels of circulating CXCL10 and FLT3LG were significantly associated with poor overall survival and EFS independently of metastasis. We further combined CXCL10, FLT3LG, and the metastatic status into a prognostic model that significantly stratified patients into 4 risk groups. The model defined survival risks significantly better than metastasis alone for prognosis, and it may serve as a risk-stratification scheme for future clinical trials in which high-risk patients can be treated with potential targeted therapies to improve their outcomes.
Our result also showed that both CXCL10 and FLT3LG were expressed in a majority of OS tissues. patients with metastasis at diagnosis, and (C) patients without metastasis at diagnosis were stratified into 3 distinct groups: neither biomarker above the cutoff, either CXL10 or FLT3LG above the cutoff, and both biomarkers above the cutoff. Significance was determined with the 1-tailed log-rank statistic. HR 1 and HR 2 refer to the patients with high CXCL10 or FLT3LG levels and patients with high CXCL10 and FLT3LG levels, respectively, in comparison with the baseline hazard of low levels for both biomarkers. CXCL10 indicates C-X-C motif chemokine ligand 10; FLT3LG, Fms-related tyrosine kinase 3 ligand; HR, hazard ratio.
However, their tumor expression did not correlate with overall survival. This may be due to the semiquantitative nature of immunohistochemistry and/or the limited number of samples used in the tissue microarray. Despite these limitations, we observed that higher FLT3LG expression exhibited a trend toward poorer overall survival, and this is similar to the circulating FLT3G result. Therefore, larger and more quantitative studies of these 2 proteins in OS may be warranted.
CXCL10 is secreted in response to IFNG under proinflammatory conditions. 22 Circulating IFNG levels significantly correlated with survival in this study, but this was excluded from the multivariate model; this suggests that its prognostic information could be explained by CXCL10 and/or FLT3LG levels. The prognostic value of CXL10 has been demonstrated in other cancers. 23, 24 It can also serve as a paracrine factor promoting metastasis to target organs, such as the lungs, liver, and lymph nodes. 25, 26 The cognate receptor of CXCL10 is C-X-C motif chemokine receptor 3 (CXCR3), which has multiple functions in cancer. 23 Specifically, CXCL10 has higher binding affinities for the CXCR3-A isoform to promote tumor proliferation. 27 Preliminary data suggest that CXCR3 is expressed in the vast majority of OS tumors (data not shown). CXCR3 antagonist AMG487 28 can inhibit metastases in OS murine models, 29 and targeting CXCR3 inhibits metastasis without adversely affecting the host's antitumoral response in breast cancer. 30 However, high natural killer cell infiltration in solid tumors has been reported to be a good prognostic factor, and the recruitment of CXCR3-positive natural killer cells to the tumor site promotes survival in mouse models of lymphoma and melanoma. 31, 32 Therefore, further studies need to be conducted to better understand the therapeutic effect of targeting CXCR3 in OS. Conversely, FLT3LG is a growth factor that binds to FLT3 (CD135), a tyrosine kinase receptor 33 that has been implicated in cancers and specifically in leukemia. 34 Increased circulating FLT3LG levels have been observed in subjects with impaired FLT3 receptor signaling 35 and after treatment with FLT3-blocking compounds such as sunitinib. 36 To our knowledge, impaired FLT3 signaling in OS has not been reported, and patients in this study were not treated with FLT3-blocking agents. Although we demonstrated that FLT3LG was expressed in OS tumors, the cause of circulating FLT3LG elevation and the role of FLT3 signaling in OS need to be further delineated.
An interesting aspect of FLT3LG is that it has been implicated in transdifferentiating dendritic cells into osteoclasts in inflammatory environments by substituting for macrophage colony-stimulating factor, which is critical for osteoclast precursor proliferation and survival. 37, 38 Osteoclast differentiation regulates bone turnover and alters the bone niche essential for bone tumor initiation and promotion. 39 Another essential factor in osteoclast differentiation is RANKL, 40 whose receptor, RANK, is associated with poor disease-free survival in OS. 41 The Children's Oncology Group is conducting a phase 2 clinical trial using the RANKL inhibitor denosumab for recurrent or refractory OS. In contrast, a recent study suggested that FLT3LG could negatively regulate osteoclast formation. 42 Furthermore, FLT3 signaling is important for host immune system maintenance because it increases the formation of regulatory T cells, 36 and FLT3LG-induced killer dendritic cells produced in mice can eliminate OS cells in vitro. 43 Therefore, potential therapeutic benefits from targeting the FLT3 axis in OS are still unclear and need to be further explored.
Although CCL4 was excluded from our final prognostic model, it was the only biomarker that significantly discriminated OS patients from normal controls. STAT3, a transcription factor for CCL4, has been shown to promote OS metastatic progression. 44 Furthermore, CCL4 has been associated with inflammation-mediated prostate and liver cancers, 45 whereas higher circulating CCL4 levels, along with CCL5, were predictive of hepatocellular tumors in patients with cirrhosis. 46 Thus, circulating CCL4 may have functional and early-detection relevance in OS.
Despite the encouraging results, we recognize limitations in the current study. Although we controlled for the collection protocol, time of sample collection, and known clinical factors, there may be unknown confounding factors for outcomes in this retrospective analysis. Thus, conducting a prospective biomarker study in a future clinical trial will address these limitations and provide additional prognostic validation.
We believe that this study is the first to report on the prognostic significance of circulating CXCL10 and FLT3LG in OS patients. It has a high clinical impact because these biomarkers could potentially guide therapies as well. Our results may be applicable to other cancers such as melanoma, colon cancer, and breast cancer, in which CXCR3 ligands are associated with tumorigenesis and metastasis, 22, 23 and other bone tumors where bone niche plays an important role, such as Ewing sarcoma. 39 Hence, upon further investigation, CXCL10/CXCR3 and FLT3LG/FLT3 axes may lead to biomarker-guided therapies not only for OS but also for other types of cytokine-driven tumors. 
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